Abstract
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD progression despite current therapies, which tends to worsen with more advanced CKD. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, decreased the risk of kidney and cardiovascular (CV) outcomes in phase III trials for patients with CKD and T2D. Combining finerenone with other CKD in T2D therapies, such as sodium-glucose co-transporter-2 inhibitors (SGLT-2is) is of interest, but more data are needed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
